EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 3.0

The Lactate Dehydrogenase-to-Albumin Ratio (LAR) for Estimating Survival in Surgically Treated Breast Cancer Patients Undergoing Subsequent Radiotherapy: A Single-Center Retrospective Cohort Study

Fen Zhang, Pengpeng Pu, Qin Zhang, Yanhua Han, Huacheng Li, Lining Jia

Breast Cancer: Targets and Therapy · 2026-11 · Volume 18 · 1-19

DOI: 10.2147/bctt.s645069 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-11. Verfasst von Fen Zhang und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The lactate dehydrogenase-to-albumin ratio (LAR), a composite biomarker integrating tumor metabolic activity and host systemic inflammatory / nutritional status, has been proven to carry prognostic value in multiple solid tumors. The current study aims to investigate its clinical significance and application in prognostic modeling for breast cancer patients receiving radiotherapy after surgery.

Methods

This study enrolled 127 female patients diagnosed with invasive breast carcinoma who received postoperative adjuvant radiotherapy at our hospital. This study determined the optimal LAR cutoff value of 4.1 in this cohort using the X-tile software, and stratifying patients into low LAR group (< 4.1, n=87) and high LAR group (≥ 4.1, n=40). Chi-square test was used to analyze correlations between LAR and clinicopathological parameter. Kaplan-Meier method was applied for survival comparison, and univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. Nomograms for 1-, 3- and 5-year disease-free survival (DFS) and overall survival (OS) were constructed and internally validated.

Results

Subsequent univariate together with multivariate Cox regression analyses validated that LAR was an independent adverse prognostic factor for both DFS (HR=3.177, 95% CI: 1.622– 6.223, P=0.001) and OS (HR=2.904, 95% CI: 1.474– 5.720, P=0.002). Patients in low LAR group achieved superior survival outcomes (DFS: χ 2 = 4.874, P = 0.0273; OS: χ 2 = 5.489, P=0.0191). The LAR-incorporated nomograms reached a C-index of 0.852 for DFS and 0.854 for OS. Calibration curves, decision curve analysis and time-dependent ROC confirmed excellent predictive accuracy and higher clinical net benefit of the models.

Conclusion

LAR is an independent and easily accessible prognostic biomarker for both DFS and OS in breast cancer patients receiving postoperative radiotherapy. The LAR-integrated nomograms can serve as a practical clinical tool to facilitate precise risk stratification and individualized survival prediction.

Zitieren

APA

Zhang, F., Pu, P., Zhang, Q., Han, Y., Li, H., & Jia, L. (2026). The Lactate Dehydrogenase-to-Albumin Ratio (LAR) for Estimating Survival in Surgically Treated Breast Cancer Patients Undergoing Subsequent Radiotherapy: A Single-Center Retrospective Cohort Study. Breast Cancer: Targets and Therapy, Volume 18, 1-19. https://doi.org/10.2147/bctt.s645069

Vancouver

Zhang F, Pu P, Zhang Q, Han Y, Li H, Jia L. The Lactate Dehydrogenase-to-Albumin Ratio (LAR) for Estimating Survival in Surgically Treated Breast Cancer Patients Undergoing Subsequent Radiotherapy: A Single-Center Retrospective Cohort Study. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-19. doi:10.2147/bctt.s645069

BibTeX
@article{Zhang2026,
  author = {Zhang, Fen and Pu, Pengpeng and Zhang, Qin and Han, Yanhua and Li, Huacheng and Jia, Lining},
  title = {The Lactate Dehydrogenase-to-Albumin Ratio (LAR) for Estimating Survival in Surgically Treated Breast Cancer Patients Undergoing Subsequent Radiotherapy: A Single-Center Retrospective Cohort Study},
  journal = {Breast Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 18},
  pages = {1--19},
  doi = {10.2147/bctt.s645069}
}
Kostenlos starten →